REGISTER
Prof. Ying Yuan: Precision + Immunotherapy Reshapes CRC Treatment
At CSCO BOC 2026, Prof. Ying Yuan of Zhejiang University reviewed CRC advances across precision and immunotherapy. In mCRC: MSI-H/dMMR immunotherapy remains standard; BRAF V600E now guideline-classified for BRAFi + cetuximab + chemo (BREAKWATER). In locally advanced pMMR rectal cancer, China leads with neoadjuvant chemoradiation + immunotherapy (3-year DFS >90% vs 70%).

Introduction

During the Chinese Society of Clinical Oncology Annual Advances Symposium (BOC) and Best of CSCO 2026 China meeting, MedJ opened its “Researcher Insights” interview room and invited Prof. Ying Yuan of the Second Affiliated Hospital, Zhejiang University School of Medicine to systematically address diagnostic and therapeutic breakthroughs in colorectal cancer (CRC), Chinese original research, and future research directions under the two core themes of “precision” and “immunotherapy.” This article summarizes the highlights.

About the Expert — Prof. Ying Yuan

  • Chief, Department of Medical Oncology, Second Affiliated Hospital of Zhejiang University
  • Chief physician, doctoral supervisor
  • Deputy Director, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education
  • Standing Deputy Editor-in-Chief and Editorial Director, Journal of Practical Oncology
  • First China Young Scientist Award in Oncology (2016)
  • Third National Renowned Physician Outstanding Demeanor Award (2019)
  • President-Elect, Zhejiang Medical Association Oncology Branch
  • Chair, Zhejiang Anti-Cancer Association Hereditary Tumor Committee
  • Standing Council member, Chinese Society of Clinical Oncology (CSCO)
  • Vice Chair, CSCO Colorectal Cancer Expert Committee
  • Standing Committee member, CSCO Gastric Cancer Expert Committee
  • Standing Committee member, China Anti-Cancer Association Tumor Clinical Chemotherapy Committee
  • Standing Committee member, China Anti-Cancer Association Colorectal Cancer Committee; Lead, Genetics Group
  • Vice Chair, China Anti-Cancer Association Cancer Supportive Treatment Committee

Precision + Immunotherapy Reshape the New Landscape of Advanced CRC Care

Prof. Yuan opened the interview by summarizing that the core advances in CRC in 2026 can be distilled into the two key themes of precision medicine and immunotherapy. These two concepts run through the full continuum of metastatic (M1) and non-metastatic (M0) CRC, and this year’s major achievements are anchored on these two dimensions.

1. Precision Medicine

In advanced metastatic CRC (mCRC), the standardized popularization of molecular testing is the foundational pillar for implementing precision therapy. Prof. Yuan emphasized that a standardized testing system has now been established in clinical practice. Guidelines explicitly recommend that all advanced CRC patients undergo routine MMR, MSI, KRAS, NRAS, and BRAF testing. For patients who have failed standard treatment, comprehensive genomic profiling should be further completed to provide precise basis for subsequent targeted and immunotherapy regimen selection.

Driven by precise classification, targeted therapy technology continues to innovate, and CRC care has welcomed two key advances.

First, the MSI-H/dMMR population remains the priority population for immunotherapy, and the concept of prioritizing immunotherapy has become fully widespread as the clinical standard of care.

Second, the 2026 guidelines formally classify BRAF V600E-mutant CRC patients as a distinct subtype, specifying that first-line treatment for these patients differs from ordinary CRC, recommending a fluoropyrimidine-based two-drug chemotherapy regimen combined with a BRAF inhibitor plus cetuximab targeted combination. This recommendation, supported by the international BREAKWATER study, has substantially improved the treatment landscape for BRAF V600E-mutant patients.

2. Immunotherapy

Addressing the challenges of immunotherapy in advanced CRC, Prof. Yuan noted that, while immunotherapy for the small MSI-H/dMMR population has matured, the majority of advanced CRC patients (those with pMMR, accounting for over 90%) remain in a bottleneck stage. In prior small-sample, single-arm Phase 2 exploratory studies, the efficacy of chemotherapy + anti-angiogenic + PD-1 inhibitor combination regimens has been inconsistent, with no unified conclusion.

Currently, two relevant Phase 3 clinical studies in China have completed enrollment and entered follow-up. Over the next 3-5 years, a series of bispecific antibody-related clinical study results will be released successively, which may solve the immunotherapy challenge in pMMR advanced CRC and improve the precision immunotherapy system for this population.

Perioperative Precision and Immunotherapy: China-Leading Breakthroughs

For non-metastatic (M0) perioperative CRC, Prof. Yuan noted that the two core concepts of precision and immunotherapy similarly dominated this year’s progress.

1. Continued Breakthroughs in Bowel Cancer; Strong Neoadjuvant Immunotherapy Efficacy

In locally advanced pMMR rectal cancer, Chinese guidelines were the first globally to innovatively include “immunotherapy combined with neoadjuvant chemoradiation” as a recommended regimen in 2025, ahead of European and American guidelines. In 2026, multiple long-term follow-up data further confirmed the clinical benefit of this regimen. For example, a study from Sun Yat-sen University Cancer Center showed that, in locally advanced pMMR rectal cancer patients using chemoradiation plus immunotherapy neoadjuvant regimen, the 3-year disease-free survival (DFS) rate exceeded 90%, a 20-percentage-point improvement compared with the 70% achieved with traditional regimens.

Prof. Yuan emphasized that these achievements from Chinese research are a major leap in perioperative treatment of locally advanced CRC, fully demonstrating the leading position of Chinese diagnostic and treatment protocols and clinical research in this field.

Building on this, Chinese investigators have further extended the successful rectal cancer experience to colon cancer, achieving another breakthrough. For example, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the preliminary results of the TORCH-C study were first reported, targeting T4 and bulky colon cancer patients with a novel neoadjuvant regimen of short-course radiotherapy + chemotherapy + immunotherapy, with a pathological complete response (pCR) rate exceeding 40%, reaching up to 50% — a striking efficacy.

Prof. Yuan noted: “The introduction of perioperative immunotherapy not only substantially improves the pCR rate in pMMR CRC patients, but has also been confirmed to translate into long-term survival benefit, providing a new path toward cure for locally advanced CRC.”

2. ctDNA-Guided Treatment Stratification; Precision Empowerment with Aspirin in Postoperative Adjuvant Therapy

Beyond the breakthrough advances in immunotherapy, perioperative CRC management has become increasingly refined in precision stratification, with multiple clinical hot questions gradually being answered. ctDNA testing has also been gradually applied in perioperative treatment decisions, enabling precise guidance of whether and for how long to conduct adjuvant therapy, and achieving individualized adjuvant regimen development for different populations such as postoperative ctDNA negative-to-positive conversion and persistent positivity, thereby avoiding overtreatment or undertreatment and further enhancing diagnostic and therapeutic precision.

In the precision exploration of postoperative adjuvant therapy, the individualized use of aspirin has emerged as a hot topic this year. Prior multiple retrospective studies demonstrated that postoperative aspirin reduces CRC recurrence risk and improves survival, but multiple international randomized controlled studies have shown conflicting results.

Synthesizing four authoritative RCT results, aspirin adjuvant for 3 years did not significantly improve DFS in unselected populations; however, studies that screened for PIK3CA pathway mutation-positive populations all yielded positive results, with such patients experiencing significant improvements in DFS and overall survival (OS) with 3-year aspirin consolidation administered concurrently with or following adjuvant therapy.

Prof. Yuan emphasized that this result fully demonstrates the central value of precision screening and provides a new precision intervention direction for postoperative adjuvant therapy. In the future, testing for PIK3CA pathway mutations and aspirin consolidation based on this result are expected to enter Chinese clinical guidelines as standardized individualized treatment.

Summary

At the close of the interview, Prof. Yuan summarized that in 2026 CRC care has achieved comprehensive breakthroughs anchored on precision classification and immunotherapy empowerment. Looking ahead, with the iterative upgrading of subgroup-targeted agents, the advance of bispecific immunotherapy regimens, and the continued refinement of precision stratification systems, CRC will move toward individualized precision care across the full disease course and full patient population, continuously improving long-term survival benefit. Chinese original research and domestic innovative drugs will continue to lead the global CRC discipline.

0
0
Loading